Introduction 45
Pathogen inactivation systems are proactive alternatives to conventional bacterial screening and 46 prevention methods for blood transfusion products [1] . 
61
Human mesenchymal stromal cells (MSCs) are multipotent cells capable of undergoing in vivo 62 differentiation into end-stage cell types of connective tissues [9]. They were initially described, in the 63 1960s, as plastic-adherent and fibroblast-like cells with clonogenic potential in vitro [10] . Today, they 64 are recognized as a part of stem cell niches in the bone marrow [11] and are known to play a role in 65 immunomodulation [12] , as demonstrated by the prominent contribution of the cells in reversing graft-66 versus-host-disease [13] . Scientific interest in MSCs has developed in recent years, making them one of 67 the most-studied human cell types related to cell-based therapy [14] .
68
An in vitro expansion step is usually necessary to attain clinically relevant numbers of MSCs 
85
Recently, emphasis has been placed on improving standardization in global good manufacturing 86 practice (GMP)-grade hPL production, as current production methods vary between manufacturers [31].
87
Although pathogen inactivation techniques have recently been introduced into the preparation of 88 transfusion products, they are predominantly applied in Europe, while blood banks in the United States
89
and Asia primarily rely on bacterial screening systems such as BacT/ALERT to ensure product safety 90
[32]. As a result, most platelets used for hPL production are currently not pathogen inactivated.
91
In this study, hPL from pathogen inactivated platelet lysates (hPL-PIPL) was compared to hPL 92 produced from conventional pathogen inactivated platelet concentrates (hPL-PIPC 
174
Chondrogenic differentiation was evaluated during 35 days of stimulation in chondrogenic media.
175
After 28 days of differentiation, the concentration of glycosaminoglycans (GAGs) was significantly 176 higher (p < 0.05) in cell pellets supplemented with both hPL-PIPC and hPL-PIPL than in unstimulated 177 control cell pellets (Fig 4) . GAG concentration remained significantly higher than the control during Based on the results obtained in this study, it appears that the application of pathogen 251 inactivation techniques after platelet expiry may prove to be a valuable tool in the pursuit of optimal 252 safety and standardization in therapeutic-grade human platelet lysate production.
254

Conclusions
255
In this study, we demonstrated that functional hPL can be produced by performing pathogen 256 inactivation after platelet lysis of expired and previously untreated platelet concentrates (hPL-PIPL). 
Preparation of platelet lysates 267
Four platelet concentrates (PCs) were prepared from a total of 32 buffy coats according to 268 standard procedure at the Blood Bank, Landspitali (The National University Hospital of Iceland),
269
Reykjavík, Iceland, as specified in freezer (Gram BioLine, Vojens, Denmark). In addition, 1 mL and 5 mL aliquots were prepared for 295 composition analysis and adipogenic differentiation, respectively, and stored at -20°C prior to analysis.
296
The hPL-PIPL units were injected into sterile bags (Cerus Corporation, Concord, CA, USA) and 16 297 exposed to pathogen inactivation with the INTERCEPT™ Blood System, according to the 298 manufacturer's protocol, before being aliquoted and stored at -20°C as above.
299
These undiluted platelet lysates were used for experimentation within 18 months of storage. 
322
The culture medium used was a complete cell culture medium (referred to as "expansion medium" 
334
Massa Martana, Italy) for a maximum of seven days.
335
Incubation was done in a Steri-Cult CO2 Incubator, HEPA Class 100 (Thermo Scientific) under 336 the following conditions: 37°C; 5% CO 2 , and 95% humidity.
337
Cell expansion was performed in different vessels appropriately selected for each experiment at 338 a seeding density of 6000 cells/cm 2 . For the initial cell expansion prior to experimentation, MSCs were 339 expanded in 20 mL of expansion medium in Nunc™ EasYFlask™ 75 cm 2 (T75) cell culture flasks 340 (Thermo Fischer Scientific Nunc A/S, Roskilde, Denmark). For long-term proliferation studies, MSCs 341 were expanded in 5 mL of expansion medium in Nunc™ EasYFlask™ 25 cm 2 (T25) cell culture flasks 342 (Thermo Fischer Scientific Nunc A/S). In both cases, the expansion medium was replaced every two to 343 three days.
344
Cell passaging was performed upon reaching 80-90% confluency, as determined visually by daily 345 inspection using a Leica DM IRB inverted contrast microscope (Leica Microsystems, Wetzlar,
346
Germany). In brief, the MSCs were gently washed with 1X PBS (Gibco) and dissociated from the 347 surface in 0.25% 1X Trypsin-EDTA (Gibco) for 5 minutes. Preheated expansion medium was added to 348 neutralize the trypsin-EDTA before the cells were centrifuged at 609 × g for 5 minutes. After MSCs in passage 5 were used to evaluate in vitro tri-lineage differentiation potential. Osteogenic 375 and adipogenic differentiation were performed simultaneously using the same cell cultures.
376
Chondrogenic differentiation was performed separately due to the large number of required cells.
378
Osteogenic differentiation 379 Osteogenic differentiation was evaluated at various timepoints during 28 days of stimulation in were included by seeding 5500 cells/cm 2 in expansion media in absence of osteogenic stimulation. Plates
388
were incubated at 37°C, 5% CO 2 , and 95% humidity for up to 28 days. The cell culture medium was 389 replaced every two to three days. The left half of the 12-well plates was used to quantify ALP activity, 390 while the right half was used to detect mineralization by staining with Alizarin Red S.
391
Enzymatic activity of ALP was evaluated after 7, 14, 21, and 28 days of osteogenic differentiation.
392
Briefly, 0.02% Triton-X (Sigma-Aldrich) diluted in 1X PBS was added to all samples, and then the cells 393 were scraped off the surface and transferred to a 1.5-mL micro tube. 
419
In brief, 10,000 cells/cm 2 were seeded in triplicate Nunc™ 9 cm 2 Slideflasks (Thermo Fischer 420 Scientific Nunc A/S). Control slideflasks were included by seeding 5500 cells/cm 2 in expansion media 421 in absence of adipogenic stimulation. Sideflasks were incubated at 37°C, 5% CO 2 , and 95% humidity 422 for up to 14 days. The MSCs were allowed to reach a confluency of 50-70% in expansion media prior 423 to introduction of the adipogenic medium. The cell culture medium was replaced every two to three 424 days. Cultures in the 9 cm 2 slideflasks were washed three times in 1X PBS and fixed in 3 mL of 4% 425 paraformaldehyde and stored at 4 °C after 7 or 14 days prior to Oil Red O staining. 
439
In brief, 250,000 cells were seeded in ten 1.5-mL micro tubes containing 0.5 mL chondrogenic 440 media for each timepoint. Control micro tubes were included by seeding 250,000 cells in expansion 441 media in absence of chondrogenic stimulation. Pellets were formed by centrifugation at 152 × g using a
442
Sorvall Instruments RC5C centrifuge (Thermo Fischer Scientific). The caps were punctured with a 443 sterile needle to allow air exchange, and the tubes were incubated at 37°C, 5% CO 2 , and 95% humidity 444 for up to 35 days. After 18-24 hours, the tubes were gently agitated to detach the pellets from the wall 445 of the micro tubes. To minimize the stress on the pellets, half of the cell culture medium was replaced 446 every second day. At each sampling timepoint (14, 28, and 35 days), three pellets were analyzed for 447 GAG content and two pellets were prepared for histological staining.
448
To prepare pellets for the GAG assay, the three pellets were pooled into a micro tube containing 449 500 µL papain extraction reagent (Sigma-Aldrich). The samples were then transferred to a Grant-Bio
450
PHMT heating block (Grant Instruments Ltd, Shepreth, Cambridgeshire, UK) and fully digested at 65°C 451 for a maximum of seven hours. After digestion, the samples were centrifuged at 9660 × g and the 452 supernatants were transferred to new micro tubes and stored at -80°C.
